ResMed Q4 revenue $914.7M (+4% YoY); dividend up 5% to $0.44; acquires MEDIFOX DAN for $1B

RESMED INC

2022-FY EPS reported $5.30 revenue$3,578,127,000

Q4 revenue $914.7M (+4% YoY, +8% constant currency); GAAP diluted EPS $1.33.
Full-year revenue $3.58B (+12% YoY, +13% constant currency); GAAP EPS $5.30.
Quarterly dividend raised 5% to $0.44/share, payable Sept 22, record Aug 18.
Announced $1B acquisition of MEDIFOX DAN, a German out-of-hospital software company; expected close by Dec 31, 2022.
Lucile Blaise promoted to President of Sleep & Respiratory Care effective July 1, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.